This cross-disease efficacy suggests that aptamers effective in modulating key mediators—such as TNF-α or various interleukins—in diseases like RA or even in oncology could be repurposed or fine-tuned to address the multifaceted pathology of OA. This evidence concerns the gene TNF and rheumatoid arthritis.